Human Immunodeficiency Virus Type 1 Entry Inhibitors Selected on Living Cells from a Library of Phage Chemokines

ABSTRACT The chemokine receptors CCR5 and CXCR4 are promising non-virus-encoded targets for human immunodeficiency virus (HIV) therapy. We describe a selection procedure to isolate mutant forms of RANTES (CCL5) with antiviral activity considerably in excess of that of the native chemokine. The phage-displayed library of randomly mutated and N-terminally extended variants was screened by using live CCR5-expressing cells, and two of the selected mutants, P1 and P2, were further characterized. Both were significantly more potent HIV inhibitors than RANTES, with P2 being the most active (50% inhibitory concentration of 600 pM in a viral coat-mediated cell fusion assay, complete protection of target cells against primary HIV type 1 strains at a concentration of 10 nM). P2 resembles AOP-RANTES in that it is a superagonist of CCR5 and potently induces receptor sequestration. P1, while less potent than P2, has the advantage of significantly reduced signaling activity via CCR5 (30% of that of RANTES). Additionally, both P1 and P2 exhibit not only significantly increased affinity for CCR5 but also enhanced receptor selectivity, retaining only trace levels of signaling activity via CCR1 and CCR3. The phage chemokine approach that was successfully applied here could be adapted to other chemokine-chemokine receptor systems and used to further improve the first-generation mutants reported in this paper.

[1]  T. Hope,et al.  Association of Chemokine-mediated Block to HIV Entry with Coreceptor Internalization* , 2002, The Journal of Biological Chemistry.

[2]  T. Schwartz,et al.  Molecular Determinants of Receptor Binding and Signaling by the CX3C Chemokine Fractalkine* 210 , 2001, The Journal of Biological Chemistry.

[3]  Menico Rizzi,et al.  Structural determinants of CCR5 recognition and HIV-1 blockade in RANTES , 2001, Nature Structural Biology.

[4]  S. Ferguson,et al.  Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. , 2001, Pharmacological reviews.

[5]  O. Chaloin,et al.  Donor- and Ligand-Dependent Differences in C-C Chemokine Receptor 5 Reexpression , 2001, Journal of Virology.

[6]  R. Nibbs,et al.  Aminooxypentane Addition to the Chemokine Macrophage Inflammatory Protein-1αP Increases Receptor Affinities and HIV Inhibition* , 2000, The Journal of Biological Chemistry.

[7]  M. Bolognesi,et al.  Enhancement of the HIV‐1 inhibitory activity of RANTES by modification of the N‐terminal region: dissociation from CCR5 activation , 2000, European journal of immunology.

[8]  John P. Moore,et al.  New targets for inhibitors of HIV-1 replication , 2000, Nature Reviews Molecular Cell Biology.

[9]  R. Offord,et al.  Amino-terminally Modified RANTES Analogues Demonstrate Differential Effects on RANTES Receptors* , 1999, The Journal of Biological Chemistry.

[10]  K. Jarnagin,et al.  Identification of residues in the monocyte chemotactic protein-1 that contact the MCP-1 receptor, CCR2. , 1999, Biochemistry.

[11]  B. Walker,et al.  Enhanced Inhibition of Human Immunodeficiency Virus Type 1 by Met-Stromal-Derived Factor 1β Correlates with Down-Modulation of CXCR4 , 1999, Journal of Virology.

[12]  Pascal Poignard,et al.  Highly Potent RANTES Analogues either Prevent CCR5-Using Human Immunodeficiency Virus Type 1 Infection In Vivo or Rapidly Select for CXCR4-Using Variants , 1999, Journal of Virology.

[13]  J. Marks,et al.  Targeted gene delivery to mammalian cells by filamentous bacteriophage. , 1999, Journal of molecular biology.

[14]  C. Combadière,et al.  Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. , 1998, The Journal of biological chemistry.

[15]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[16]  N. Skelton,et al.  Distinct but overlapping epitopes for the interaction of a CC-chemokine with CCR1, CCR3 and CCR5. , 1997, Biochemistry.

[17]  M. Locati,et al.  HIV-1 coreceptor activity of CCR5 and its inhibition by chemokines: independence from G protein signaling and importance of coreceptor downmodulation. , 1997, Virology.

[18]  B. Cullen,et al.  Molecular mechanism of desensitization of the chemokine receptor CCR‐5: receptor signaling and internalization are dissociable from its role as an HIV‐1 co‐receptor , 1997, The EMBO journal.

[19]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[20]  N. Heveker,et al.  Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.

[21]  T. Schwartz,et al.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. , 1997, Science.

[22]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[23]  Bernhard Moser,et al.  The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1 , 1996, Nature.

[24]  J. Sodroski,et al.  The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry , 1996, Nature.

[25]  B. Dewald,et al.  RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors (*) , 1996, The Journal of Biological Chemistry.

[26]  M. Montjovent,et al.  Extension of Recombinant Human RANTES by the Retention of the Initiating Methionine Produces a Potent Antagonist (*) , 1996, The Journal of Biological Chemistry.

[27]  S. Arya,et al.  Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV-Suppressive Factors Produced by CD8+ T Cells , 1995, Science.

[28]  Greet Vanhoof,et al.  Proline motifs in peptides and their biological processing , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[29]  R. Connor,et al.  Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. , 1995, Virology.

[30]  H R Hoogenboom,et al.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains. , 1991, Nucleic acids research.

[31]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[32]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[33]  A. Wlodawer,et al.  Total chemical synthesis and high-resolution crystal structure of the potent anti-HIV protein AOP-RANTES. , 1999, Chemistry & biology.

[34]  W. Stemmer,et al.  Construction and evolution of antibody–phage libraries by DMA shuffling , 1996, Nature Medicine.

[35]  S. Arya,et al.  Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. , 1995, Science.